MESO - Mesoblast Limited
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 3.6300 |
| Open | 3.6000 |
| Bid | 3.4400 x 1000 |
| Ask | 3.4700 x 1000 |
| Day's Range | 3.4300 - 3.6000 |
| 52 Week Range | 2.1400 - 4.3500 |
| Volume | |
| Avg. Volume | 127,701 |
| Market Cap | 563.053M |
| Beta (5Y Monthly) | 2.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.63 |
Fair Value
Related Research
GlobeNewswireMesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March 31, 2023. OPERATIONAL HIGHLIGHTS Remestemcel-L BLA filing accepted by FDA, PDUFA goal date set US Food and Drug Administration (FDA) accepted Mesoblast’s filing of the Biologics License Application (BLA) for remestemcel-L in the treatment of children wit
- GlobeNewswire
Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, May 24, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the third quarter ended March 31, 2023. The webcast will begin at 6.30pm EDT, Thursday, May 25; 8.30am AEST, Friday, May 26, 2023. It can be accessed via: https://webcast.openbriefing.com/msb-qtr1-2023/ The archived webcast will be available on the Investor pag
- GlobeNewswire
Appendix 4C Quarterly Activity Report
Mesoblast Financial and Operational Highlights for Quarter Ended March 31, 2023NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2023. Financial Highlights Successful completion of a global private placement primarily to Mesoblast’s existing major US, UK, and Australian shareholders raising approximately US$40 milli
- GlobeNewswire
Mesoblast Completes Private Placement
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has completed a global private placement primarily to Mesoblast’s existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs, at A$0.85 per share. Proceeds will be used to fund: Launch and commercialization of the company’s lead product, remestemcel-L, in the treatm
- GlobeNewswire
FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing
Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host Disease (SR-aGVHD) Currently Being Reviewed PDUFA Goal Date August 2, 2023 If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today an
BenzingaWilliam Blair Initiates Mesoblast Soon After Its Lead Product Goes Under FDA Review In Pediatric Indication
William Blair has initiated coverage on Mesoblast Ltd (NASDAQ: MESO) with an Outperform rating and a price target of $8. Mesoblast's lead product, remestemcel-L, has shown transformative efficacy in pediatric steroid-refractory (SR) acute graft-versus-host disease (aGvHD), where no approved therapies exist for children under the age of 12. In a Phase 3 trial, 69% of pediatric SR-aGvHD patients treated with remestemcel-L were alive at day 180, and 51% were alive two years after treatment vs. 49%
ZacksMesoblast's (MESO) GVHD Drug BLA Gets FDA Priority Tag, Stock Up
Mesoblast (MESO) announces the FDA acceptance for review of the resubmitted biological license application for remestemcel-L for the treatment of children under 12 with steroid-refractory acute graft versus host disease. Stock gains on Wednesday, following the news.
BenzingaMesoblast's Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids
Mesoblast Ltd (NASDAQ: MESO) rallied after the FDA agreed to review the company's lead drug candidate, remestemcel-L, on a priority basis, more than two years after first rejecting it. The drug is an investigational therapy that comprises culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. The product is under priority review for children suffering from steroid-refractory acute graft versus host disease (SR-aGVHD). The FDA said it considered Mesoblast's
- GlobeNewswire
FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023
If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD.NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Therapeutic Products (OTP) has accepted the Company’s Biologics License Application
Simply Wall St.Mesoblast Second Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag
Mesoblast ( ASX:MSB ) Second Quarter 2023 Results Key Financial Results Net loss: US$24.5m (loss narrowed by 5.6% from...
- GlobeNewswire
Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended December 31, 2022. Dr. Silviu Itescu, Chief Executive of Mesoblast, commenting on the results said, “There is an urgent need for a therapy that improves the dismal survival outcomes in children with steroid-refractory acute graft versus host disease (SR-aGVHD
- GlobeNewswire
DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)
Single Intra-Myocardial Intervention with Rexlemestrocel-L Reduced Cardiovascular Death, Myocardial Infarction or Stroke Over Mean Follow-Up of 30 Months in High-Risk Patients with Chronic Heart FailureNEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the Jo
- Simply Wall St.
The past three years for Mesoblast (ASX:MSB) investors has not been profitable
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
- GlobeNewswire
Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy
NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that two studies on the remestemcel-L development program for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) were selected by peer review to be presented at the 2023 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for Bloo
- GlobeNewswire
FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA)
- GlobeNewswire
Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action Assay Identifies High-Potency Product Lots Associated with Enhanced Survival New Data Show that Remestemcel-L Improves Inflammatory Biomarkers and Survival in Children at Highest Risk of Mortality New 4-Year Data from the Phase 3 Trial Shows Durable Long-Term Survival Outcomes BLA Resubmission will have a Review Period up to Six-Months from Filing upon Acceptance by FD
- Simply Wall St.
Multiple insiders bought Mesoblast Limited (ASX:MSB) stock earlier this year, a positive sign for shareholders
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Insider MonkeyMesoblast Limited (NASDAQ:MESO) Q1 2023 Earnings Call Transcript
Mesoblast Limited (NASDAQ:MESO) Q1 2023 Earnings Call Transcript November 23, 2022 Dr. Silviu Itescu: Good morning, good afternoon to the operational highlights and financial results for the quarter ended September 30, 2022, as well as our upcoming Annual General Meeting. Apologies for the slight delay due to technical difficulties; beyond our control. Joining me here […]
- Simply Wall St.
Mesoblast Limited (ASX:MSB) most popular amongst individual investors who own 53% of the shares, institutions hold 36%
Every investor in Mesoblast Limited ( ASX:MSB ) should be aware of the most powerful shareholder groups. The group...
GlobeNewswireMesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that funds managed by Oaktree Capital Management, L.P. (“Oaktree”) have extended to Mesoblast the availability of up to an additional US$30.0 million of its US$90 million five year facility subject to achieving certain milestones on or before September 30, 2023. Mesoblast drew the first tranche of US$60 million in November
ZacksMesoblast Limited (MESO) Upgraded to Buy: Here's What You Should Know
Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Simply Wall St.
Mesoblast Limited's (ASX:MSB) Shift From Loss To Profit
We feel now is a pretty good time to analyse Mesoblast Limited's ( ASX:MSB ) business as it appears the company may be...
BenzingaMesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease
Mesoblast Limited (NASDAQ: MESO) announced top-line long-term survival results for remestemcel-L from its Phase 3 trial (GVHD-001) in children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed durable survival through 4 years of follow-up. These new long-term survival data are a key component of the company's BLA resubmission to the FDA for remestemcel-L in treating children with SR-aGVHD. A four-year observational cohort survival study was performed on 51 ev
- GlobeNewswire
Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only approved agent in adults1-4These results reaffirm the potential significance of remestemcel-L as a life-saving therapy for children with SR-aGVHDThese long-term survival outcome
- GlobeNewswire
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These long-term survival outcomes are a cornerstone of the BLA resubmission to FDA for approval of remestemcel-L in the treatment of children with SR-aGVHD NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational high